score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	MET	Amplification				0.0	0.0		Putatively Actionable	Crizotinib	MET inhibition	Targeted therapy	Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				MET Amplification	0.0	MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5299	485.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat100		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site		0.6316	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53  (Splice Site)		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.R1013Q	0.028999999999999998	138.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0				ABL1 p.R1013Q (Missense)		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S259F	0.0897	156.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SETBP1 p.S259F (Missense)		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat100		
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Frameshift	p.N1087fs	0.2739	314.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.N1087fs (Frameshift)	1.0	MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Frameshift	p.N1087fs	0.2299	374.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.N1087fs (Frameshift)	1.0	MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.R231K	0.151	245.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				RAD51B p.R231K (Missense)	0.0	MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Investigate Actionability	Preclinical			Copy Number	AURKB	Deletion				0.0	0.0		Investigate Actionability	Barasertib	Aurora-B kinase inhibition	Targeted therapy	MYC amplified small cell lung cancer	Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.	https://doi.org/10.1158/1535-7163.MCT-16-0298													0				AURKB Deletion		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L2022F	0.2019	416.0	0.0	0.0																					0				MTOR p.L2022F (Missense)		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Biologically Relevant				Somatic Variant	TACC3	Splice Site		0.4742	310.0	0.0	0.0																					0				TACC3  (Splice Site)		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Biologically Relevant				Somatic Variant	NF1	Missense	p.L499P	0.4724	163.0	0.0	0.0																					0				NF1 p.L499P (Missense)		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R470C	0.1771	96.0	0.0	0.0																					0				KEAP1 p.R470C (Missense)		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	MEL-IPI_Pat100-Normal-SM-53U4M
Biologically Relevant				Copy Number	EZH2	Amplification				0.0	0.0																					0				EZH2 Amplification		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Biologically Relevant				Copy Number	POT1	Amplification				0.0	0.0																					0				POT1 Amplification		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Biologically Relevant				Copy Number	MPL	Amplification				0.0	0.0																					0				MPL Amplification		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Biologically Relevant				Copy Number	GATA3	Deletion				0.0	0.0																					0				GATA3 Deletion		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Biologically Relevant				Copy Number	FLCN	Deletion				0.0	0.0																					0				FLCN Deletion		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Biologically Relevant				Copy Number	PDGFRB	Deletion				0.0	0.0																					0				PDGFRB Deletion		MEL-IPI_Pat100	MEL-IPI_Pat100-Tumor-SM-53U2D	
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH3 Deletion, MSH3 p.PPA66del (Deletion)																									0				Supporting variants: MSH3 Deletion, MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat100		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.217																									0				COSMIC Signature (version 2) 1 (22%)		MEL-IPI_Pat100		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.718																									0				COSMIC Signature (version 2) 7 (72%)		MEL-IPI_Pat100		
